Bonus Biogroup has received FDA approval for an IND application to conduct a Phase III clinical trial of a drug designed to treat acute respiratory distress syndrome (ARDS), especially in severe COVID ...

Aridis Pharmaceuticals Inc (NASDAQ: ARDS) shares are gaining after announcing positive European Medicines Agency feedback on its proposed single confirmatory Phase 3 study of investigational ...

Following positive results in Phase 2 studies, the company has reached an agreement with regulatory authorities on manufacturing details and is preparing for commercial production. Plans are ...

Sabizabulin, a microtubule disruptor, is being developed as a Phase 3 clinical trial for the treatment of hospitalized patients with viral-induced ARDS. The Company does not intend to undertake ...